ASCO GU 2025: new data confirms triplet therapy benefits, especially with darolutamide

[Maxone73]

A new population-adjusted analysis confirms that the combination of darolutamide, ADT, and docetaxel significantly improves survival in men with metastatic hormone-sensitive prostate cancer (mHSPC).

By using advanced statistical methods to adjust for differences in patient populations across 12 clinical trials, researchers found that this triplet therapy consistently outperformed other commonly used treatments, including abiraterone + ADT + docetaxel, abiraterone + ADT, enzalutamide + ADT, apalutamide + ADT.

The ML-NMR approach provided the most robust evidence, while the NMI method, though supportive, was limited by incomplete subgroup data. Patients on the darolutamide triplet had a significantly lower risk of death, reinforcing it as a top-tier standard of care for mHSPC.

Let's hope!!!

prostatewarriors.com/2025/0...

[Wagon-Wheel]

Thanks, Max. I started triplet therapy in September of 2022 with Darolutamide. My first MO gave me a three year prognosis (Gleason 10, one bone met on S1, two pelvic lymph node mets). It was devastating since I had two kids in middle school and one in high school. I am always happy to hear about any research that means I get more time with them.

[Maxone73 in reply to Wagon-Wheel]

Keep fighting! We are getting closer...

[EdBar in reply to Wagon-Wheel]

Ya I was given the same 3 year prognosis almost 11 years ago. I was dx G9 stage 4, lots of mets throughout my skeleton and nodes. You can read my profile to see what treatments I’ve used. Get an onco who specializes in prostate cancer not just a general onco, hit it hard early on and prayers, lots of prayers, these are the things that worked for me.

Ed

[littleCar]

Good news! Thanks brightening my day Max!🙏

[Maxone73 in reply to littleCar]

You are welcome! Fight on!